Jennifer E. Miller, PhD is a fellow in the Edmond J. Safra Center for Ethics at Harvard University. Prior to joining Harvard’s ethics center, she taught in Columbia University's Bioethics Program and in Fordham University's Graduate School of Business. In the fall, Dr. Miller will also join Duke University’s Kenan Institute for Ethics, jointly appointed by the Fuqua School of Business and Trinity College of Arts and Sciences.
Her academic career is complemented by a strong record of public service, including serving (2009-2011) on the US Taskforce for Pediatric Emergency Mass Critical Care under the Centers for Disease Control & Prevention (tasked with developing a national framework for the responsible allocation of limited healthcare resources), as a consultant to the United Nations ECOSOC (organ facilitating international cooperation on standards-making and problem-solving in economic and social issues), on the AMA's National Disaster Life Support Education Consortium, and as the Founding President of the NYC based nonprofit Bioethics International (2005-present).
Her expertise has been widely featured in the foreign and domestic press, including on Fox News, CBS News, AP News, NPR and the cover of Science Magazine’s Career section. She has authored numerous articles on a wide range of bioethical issues--- including the role of religion in bioethics, personalized medicine, triage ethics, institutional corruption, research ethics, access to medicines, and the role of globalization, markets and governance in healthcare innovation--- for Nature Medicine, the Scientist, the Journal of Law Medicine and Ethics, the Hastings Center Report and other scholarly journals.
Her current work assesses the state of ethics and trust in the pharmaceutical industry and explores whether a bioethics rating system can help fix genuine and widespread problems. To this end, she created and has completed a pilot of a rating index that assesses and signals the degree to which the 20 largest drug and biotechnology companies publically communicate the results of their clinical trials for newly approved drugs.